“Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients with Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s403. doi:10.25251/skin.8.supp.403.